Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.50 |
| ▸ | FGFR4 | P22455 | 13/20 | 0.50 |
| ▸ | KDR | P35968 | 13/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31466904 | 0.90 | FGFR1 (0.44) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL31466999 | 0.89 | FGFR1 (0.43) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL23328287 | 0.87 | FGFR1 (0.55) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL20942985 | 0.84 | FGFR1 (0.39) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL31466893 | 0.83 | FGFR1 (0.38) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL31466891 | 0.81 | FGFR1 (0.37) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL23328310 | 0.81 | FGFR1 (0.49) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL15412605 | 0.80 | FGFR1 (0.58) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL31466843 | 0.80 | FGFR1 (0.43) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL19499682 | 0.77 | FGFR4 (0.52) | FGFR1FGFR4KDRFGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| WO-2020038458-A1 | CLASS OF FUSED RING TRIAZOLE COMPOUND, PREPARATION METHOD, AND USE | 如东凌达生物医药科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | FGFR1, FGFR4, FGFR2 | FGFR1 1/4885FGFR4 2/4885KDR 12/4885 |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | FGFR1, FGFR4, FGFR2 | FGFR1 1/4885FGFR4 2/4885KDR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.